Multiple sclerosis trials in Poland

In Poland 23 Also abroad 506

22 of 23 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis
Where
Bydgoszcz, Cracow, Gdansk, Katowice, Lodz, Lublin, Nowa Sol, Olsztyn, Plewiska, Poznan, Rzeszów, Szczecin, Warsaw, Zabrze, Zory
Age
18 years to 60 years
People
705 worldwide
Run by
Zenas BioPharma (USA), LLC
See details and how to joinNCT07067463 · EU 2025-524316-11-00
Phase 2Taking people
A Pharmacokinetics (PK), Pharmacodynamics (PD), Safety and Tolerability Study of Fenebrutinib in Children and Adolescents With Relapsing Multiple Sclerosis (RMS)
Where
Gdansk, Poznan, Warsaw
Age
10 years to 17 years
People
12 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT07161258 · EU 2024-519800-28-00
Phase 3Taking people
A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis
Where
Bydgoszcz, Cracow, Gdansk, Katowice, Lodz, Łódź, Lublin, Nowa Sol, Olsztyn, Plewiska, Poznan, Rzeszów, Szczecin, Warsaw, Zory
Age
18 years to 60 years
People
990 worldwide
Run by
Zenas BioPharma (USA), LLC
See details and how to joinNCT07299019 · EU 2025-524322-18-00
Phase 2Taking people
Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368, a FAAH/MAGL Inhibitor, in Participants with Multiple Sclerosis Spasticity
Where
Bydgoszcz, Cracow, Katowice, Krakowie, Lodz, Oswiecim, Warsaw
Age
18 years and over
People
100 worldwide
Run by
Celgene Corp.
See details and how to join2024-517745-14-00 · EU 2024-517745-14-00
Phase 2/3Taking people
Study to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of Multiple Sclerosis
Where
Gdansk, Katowice, Lodz, Poznan, Rzeszów, Warsaw
Age
10 years to 17 years
People
240 worldwide
Run by
TG Therapeutics, Inc.
See details and how to joinNCT07220252 · EU 2025-522257-19-00
Phase 2Taking people
A Study to Evaluate Pharmacokinetics (PK) and Safety of Subcutaneous (SC) Ublituximab Administered at Various Injection Sites and Relative Bioavailability Via Autoinjector (AI) Versus Syringe Subcutaneously in Participants With Multiple Sclerosis (MS)
Where
Bydgoszcz, Cracow, Katowice, Kielce, Łódź, Olsztyn, Poznan, Warsaw, Zabrze
Age
18 years to 65 years
People
350 worldwide
Run by
TG Therapeutics, Inc.
See details and how to joinNCT07503873 · EU 2025-523757-33-00
Phase 3Taking people
Efficacy and safety study of frexalimab (SAR441344) in adults with relapsing forms of multiple sclerosis
Where
Bydgoszcz, Katowice, Plewiska k. Poznania, Rzeszow, Zabrze, Zory
Age
18 years to 64 years
People
386 worldwide
Run by
Sanofi-Aventis Recherche & Developpement
See details and how to join2023-504358-36-00 · EU 2023-504358-36-00
Phase 2Taking people
A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity
Where
Bydgoszcz, Gdansk, Katowice, Krakow, Lodz, Oświęcim, Słomniki, Warsaw
Age
18 years to 70 years
People
200 worldwide
Run by
Celgene
See details and how to joinNCT06782490
Phase 2Taking people
Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients with Progressive Multiple Sclerosis
Where
Bydgoszcz, Katowice, Kielce, Lublin, Oswiecim, Plewiska, Poznan, Szczecin, Warsaw, Wroclaw
Age
18 years to 64 years
People
230 worldwide
Run by
Immunic AG
See details and how to joinNCT05054140 · EU 2024-514617-35-00
Phase 3Taking people
Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab
Where
Bydgoszcz, Cracow, Katowice, Kielce, Łódź, Olsztyn, Poznan, Warsaw, Zabrze, Zory
Age
18 years to 65 years
People
800 worldwide
Run by
TG Therapeutics, Inc.
See details and how to joinNCT05877963 · EU 2024-519284-18-00
Phase 3Taking people
A Randomized, Double-blind, Study to Demonstrate Pharmacokinetic Similarity, and Evaluate Safety, Immunogenicity, Pharmacodynamics and Clinical Effects between ABP 692 and Ocrevus® (Ocrelizumab) in Subjects with Relapsing-remitting Multiple Sclerosis
Where
Bydgoszcz, Cracow, Katowice, Kielce, Łódź, Lublin, Warsaw
Age
18 years to 64 years
People
125 worldwide
Run by
Amgen Inc.
See details and how to join2024-512914-16-00 · EU 2024-512914-16-00
Phase 2Not yet taking people in Poland
A Study to Evaluate Pharmacokinetics, Safety, Tolerability, Immunogenicity and Pharmacodynamic Effects of Subcutaneous Ocrelizumab Administration in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS)
Where
Gdansk, Poznan, Warsaw
Age
10 years to 17 years
People
25 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT07503340 · EU 2025-524164-37-00
Phase 3Taking people
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
Where
Bydgoszcz, Chojnice, Katowice, Krakow, Lodz, Lublin, Rzeszów, Skorzewo, Szczecin, Warsaw, Zabrze, Żory
Age
18 years to 65 years
People
1,275 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT07225504
Phase 3Taking people
Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis
Where
Bialystok, Bydgoszcz, Cracow, Katowice, Kielce, Łódź, Plewiska k. Poznania, Poznan, Rzeszow, Zabrze, Zory
Age
18 years to 60 years
People
160 worldwide
Run by
Sanofi
See details and how to joinNCT07325292 · EU 2026-525688-41-00
Phase 2Taking people
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)
Where
Bydgoszcz, Cracow, Gdansk, Katowice, Kielce, Krakowie, Lodz, Lublin, Poznań, Rzeszow, Rzeszów, Warsaw, Wrocław, Zabrze, Zory
Age
18 years to 60 years
People
360 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT07282574 · EU 2025-521636-10-00
Phase 3Taking people
Efficacy and safety of ofatumumab and siponimod compared to fingolimod in pediatric patients with multiple sclerosis
Where
Gdansk, Lodz, Poznan, Warsaw
Age
Up to 17 years
People
64 worldwide
Run by
Novartis Pharma AG
See details and how to join2024-511686-11-00 · EU 2024-511686-11-00
Phase 3Taking people
Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis
Where
Poznan
Age
10 years to 17 years
People
194 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT06408259 · EU 2022-501332-42-00
Phase 2Taking people
A Phase 2 Study of Obexelimab in Patients with Relapsing Multiple Sclerosis
Where
Bydgoszcz, Katowice, Lublin, Zabrze
Age
18 years to 64 years
People
93 worldwide
Run by
Zenas Biopharma (USA) LLC
See details and how to join2024-512707-40-00 · EU 2024-512707-40-00
Phase 3Taking people
A clinical trial to find out how well LOU064 (remibrutinib) works and how safe it is for people with secondary progressive multiple sclerosis
Where
Bydgoszcz, Chojnice, Cracow, Katowice, Lodz, Lublin, Rzeszów, Skorzewo, Szczecin, Warsaw, Wrocław, Zabrze, Zory
Age
18 years and over
People
677 worldwide
Run by
Novartis Pharma AG
See details and how to join2025-521546-23-00 · EU 2025-521546-23-00
Phase 1Not yet taking people in Poland
A Biosimilar Trial to Investigate PK, PD, Safety With PB018 Versus US-licensed Ocrevus and EU-approved Ocrevus
Where
Bydgoszcz, Cracow, Katowice, Klodzko, Lublin, Olsztyn, Skorzewo, Zabrze
Age
18 years to 65 years
People
222 worldwide
Run by
Polpharma Biologics International AG
See details and how to joinNCT07606521 · EU 2026-525314-61-00
Phase 3Taking people
A Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients With Relapsing-remitting Multiple Sclerosis
Where
Poznan
Age
18 years to 55 years
People
512
Run by
Celltrion
See details and how to joinNCT05906992
Phase 2/3Taking people
Cladribine vs Placebo for Non-active Progressive Multiple Sclerosis (CLASP-MS).
Where
Warsaw
Age
30 years to 65 years
People
188
Run by
Institute of Psychiatry and Neurology, Warsaw
See details and how to joinNCT05961644 · EU 2024-516992-33-02